RIGA - Latvian pharmaceutical company Grindex has received a certification of Saudi Food and Drug Authority, the company said in its statement to the Nasda Riga stock exchange.
The company's representatives said that this certifies the compliance of Grindex final dosage forms –tablets and capsules – with the Saudi Arabia’s medicines manufacturing requirements.
“The positive assessment of the compliance of Grindex final dosage forms manufacturing site with the Saudi Arabia’s pharmaceutical manufacturing standard opens us new export opportunities to the Middle East region. The Saudi Food and Drug Authority is very demanding and rigorous, which is why its certification is highly valued in other Gulf countries," said Grindex Chairman of the Board Juris Bundulis.
The company also said that in recent years Grindex has been strategically expanding the range of oncological medicines therefore medicines of this therapeutic group will be the first with which Grindex plans to enter the Saudi Arabia’s market.
At the same time, the Saudi Food and Drug Authority is organizing an inspection at HBM Pharma in Slovakia, a subsidiary of Grindex, to evaluate the compliance of injections solutions with Saudi Arabia’s medicines manufacturing requirements.
The Grindex group comprises the parent company, Grindex, and five subsidiaries in Latvia, Estonia, Russia and Slovakia. Grindex is quoted on the Main List of Nasdaq Riga stock exchange.